NDAORALTABLET
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUTOPAR (ritodrine hydrochloride) is an oral small-molecule beta-2 adrenergic agonist approved in 1980 for the treatment of premature labor and preterm birth prevention in pregnant women. The drug works by stimulating beta-2 adrenergic receptors on uterine smooth muscle to inhibit uterine contractions and delay delivery.
LOE Approaching
As LOE approaches, the brand team is likely contracting and focusing on managed decline and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on YUTOPAR as a pharma professional offers limited career growth potential given its LOE-approaching status and minimal linked job openings (0 positions). Roles available are primarily defensive, focused on market maintenance and smooth generic transition rather than expansion or innovation.
Brand ManagerMedical Affairs/MSL
Worked on YUTOPAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.